ReviewPaediatric drugs2004
Neuroblastoma: evolving therapies for a disease with many faces.
Review in Paediatric drugs, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.The Cochrane database of systematic reviews · 2015Pooled it
- Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.British journal of cancer · 2005Trial
- Contrast-enhanced computed tomography radiomics in predicting primary site response to neoadjuvant chemotherapy in high-risk neuroblastoma.Abdominal radiology (New York) · 2023Article
- A novel minimal residual disease model of neuroblastoma in mice.Journal of pediatric surgery · 2016Article
- Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells.Molecular & cellular proteomics : MCP · 2015Article
- Article
- Nuclear condensation and cell cycle arrest induced by telomerase siRNA in neuroblastoma cells.Journal of neuro-oncology · 2013Article
- High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.Cancer investigation · 2012Article
- Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells.Cancer letters · 2011Article
- Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells.Journal of agricultural and food chemistry · 2011Article
- Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation.PloS one · 2011Article
- Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model.Chemical biology & drug design · 2010Article
- Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells.Drug design, development and therapy · 2009Article
- Article
- Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.Journal of cellular biochemistry · 2007Article
- Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines.Bioorganic & medicinal chemistry letters · 2007Article
- Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma.Chemical biology & drug design · 2007Article
- Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR.Clinical & experimental metastasis · 2006Article
- The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro.Investigational new drugs · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Neuroblastoma is the most common extra-cranial solid tumor in children and has a heterogeneous clinical presentation and course. Clinical and biologic features of this disease have been used to develop risk-based therapy. Patients with low-risk disease can be treated with surgery alone. Patients with intermediate-risk features have an excellent prognosis after treatment with surgery and a relatively short course of standard dose chemotherapy. Unfortunately, most children with neuroblastoma present with advanced disease. More than 60% of patients with high-risk features will succumb to their disease despite intensive therapy including a myeloablative consolidation. Research efforts to understand the biologic basis of neuroblastoma and to identify new, more effective therapies are essential to improve the outcome for these children.
Indexed as
Identifiers
15035651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.